Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupREPL +1.25%27 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates REPL with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 843 Biotechnology companies, Replimune Group ranks worse than 118623.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Replimune Group's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Replimune Group's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
Replimune Group (NAS:REPL) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Replimune Group Receivables Turnover Related Terms
Replimune Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Replimune Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REPL vs ANNX, SLDB, ABUS: Receivables Turnover Comparison
For the Biotechnology subindustry, Replimune Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Replimune Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (REPL) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #999999 out of 843 companies in the Biotechnology industry.
Is Replimune Group's Receivables Turnover too high?
Replimune Group's current Receivables Turnover is 0.00. Based on the distribution chart, Replimune Group ranks #999999 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Receivables Turnover compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #999999 out of 843 companies for Receivables Turnover. This places Replimune Group in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Replimune Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (REPL) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Replimune Group (REPL), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score
Get the complete analysis for REPL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REPL has been successfully added to your 
